Acurx Pharmaceuticals Inc (ACXP) Q4 2025 Earnings Call Highlights: Financial Growth and ... [Yahoo! Finance]
Acurx Pharmaceuticals, Inc. (ACXP)
Company Research
Source: Yahoo! Finance
Equity Line of Credit Proceeds: Raised approximately $1.5 million during the quarter and $4 million for the full year 2025. Research and Development Expenses (Q4 2025): $0.3 million, a decrease from $0.8 million in Q4 2024. Research and Development Expenses (Full Year 2025): $1.8 million, down from $5.4 million in 2024. General and Administrative Expenses (Q4 2025): $1.3 million, down from $2 million in Q4 2024. General and Administrative Expenses (Full Year 2025): $6.3 million, a decrease from $8.7 million in 2024. Net Loss (Q4 2025): $1.6 million or $0.73 per diluted share, compared to $2.8 million or $3.29 per diluted share in Q4 2024. Net Loss (Full Year 2025): $8 million or $5.32 per diluted share, compared to $14.1 million or $17.45 per share in 2024. Shares Outstanding: 2,348,113 as of December 31, 2025. Warning! GuruFocus has detected 1 Warning Sign with ACXP. Is ACXP fairly valued? Test your thesis with our free DCF calculator. Release Date: March 13, 202
Show less
Read more
Impact Snapshot
Event Time:
ACXP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACXP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACXP alerts
High impacting Acurx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ACXP
News
- Is Acurx Pharmaceuticals (ACXP) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
- Acurx Pharmaceuticals, Inc. (ACXP) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business UpdatePR Newswire
- Acurx Pharmaceuticals, Inc. [CNN]CNN
- Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection [Yahoo! Finance]Yahoo! Finance
ACXP
Earnings
- 3/13/26 - Beat
ACXP
Sec Filings
- 3/12/26 - Form S-8
- 3/12/26 - Form 10-K
- 3/9/26 - Form 8-K
- ACXP's page on the SEC website